Wellma Acquires Virun NutraBiosciences, Expanding CDMO Reach into US & Ireland
Swedish CDMO Wellma has acquired US-based Virun NutraBiosciences, signalling strategic expansion into the US and Irish markets and integrating advanced emulsion and liposomal technology.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
London, United Kingdom — 27 July 2026
Swedish contract development and manufacturing organisation (CDMO) Wellma has announced the acquisition of Virun NutraBiosciences, a US-based specialist in advanced nutrient delivery systems. This strategic move marks Wellma's entry into the US and Irish markets, significantly broadening its geographical footprint and bolstering its technological capabilities. Virun, established in 2003 by Philip Bromley and Nick Huang, is renowned for its pioneering work in emulsion and liposomal technologies, holding an extensive portfolio of over 100 patents in this field. The acquisition is Wellma's thirteenth overall but their first direct investment in the US market, underscoring a concerted effort towards rapid international expansion within the nutraceutical sector.
This integration aims to leverage the combined expertise of both entities to enhance customer support and accelerate growth in key North American and European markets. For brand owners, access to Virun's patented delivery systems through Wellma potentially offers competitive advantages in product formulation, bioavailability, and market differentiation. The acquisition also signals a consolidation trend within the CDMO space, where firms are seeking to acquire specialised technologies to offer comprehensive, vertically integrated services.
The move is expected to streamline the development and manufacturing process for complex supplement formulations, particularly those requiring enhanced absorption or novel dosage forms. This consolidation could lead to increased economies of scale for Wellma, potentially influencing pricing and minimum order quantities (MOQs) for advanced formulation projects across their expanded network. Competitors in the CDMO market will need to evaluate their own innovation pipelines and service offerings to maintain parity, especially in the rapidly evolving segment of high-bioavailability ingredients.
What this means for United Kingdom
UK brand owners will gain direct access to Virun's advanced emulsion and liposomal technologies via Wellma's expanded European network, potentially reducing reformulation windows and accelerating new product development. This acquisition by a significant European CDMO could intensify competition among UK-based contract manufacturers, particularly those not offering similar high-tech delivery solutions. Procurement leads should assess Wellma's new capabilities against existing suppliers to optimise ingredient bioavailability and product efficacy, ensuring compliance with UK novel food regulations if applicable. Manufacturers not offering similar proprietary delivery systems may face pressure on margins if they cannot match the innovation proposition.
"Our partnership with Virun represents a pivotal moment in our strategy to become a leading global CDMO for the nutraceutical industry," stated a Wellma spokesperson. "The integration of Virun's innovative delivery technologies and manufacturing excellence will enable us to offer unparalleled value to our clients across Europe and the Americas."
Brand owners increasingly rely on contract-manufacturing partners such as Supplement Factory to navigate these requirements.